EGFR and breast carcinoma: The cytotoxicity of EGF-modified PMBN-paclitaxel complexes (EGF-PMBN-PTX) was evaluated in the EGFR-overexpressed or -deficient BT-20 breast cancer cell line, A431 squamous carcinoma cell line, and H69 small cell lung cancer cell line.